January 2019 DAIT Council-Approved Concepts

Concepts represent early planning stages for program announcements, requests for applications, or solicitations for Council's input. If NIAID publishes an initiative from one of these concepts, we link to it below. To find initiatives, go to Opportunities & Announcements.

NB: Council approval does not guarantee that a concept will become an initiative.

Table of Contents

Fiscal Year 2020 Concepts

Fiscal Year 2020 Small Business Innovation Research (SBIR) Contract Solicitation Topics

Development of Sample Sparing Assays for Monitoring Immune Responses

For the published request for applications, see the March 27, 2019 Guide announcement, Development of Sample Sparing Assays for Monitoring Immune Responses (U24 Clinical Trial Not Allowed).

Human Leukocyte Antigen (HLA) and Killer-Cell Immunoglobulin-Like Receptor (KIR) Region Genomics in Immune-Mediated Diseases

Request for Applications—proposed FY 2020 initiative

Contact: Jeff Rice

Objective: The goal of the HLA and KIR Region Genomics in Immune-Mediated Diseases program is to define the association between variations in HLA and KIR genetic regions and immune-mediated diseases, including risk, progression, and severity of or protection from disease, and organ, tissue, and cell transplantation outcomes. Understanding the connection between these regions and disease phenotype and/or transplantation outcome will provide insight into the mechanism of disease, improve predictive power of screening, and may lead to more precise therapies. The program will also continue to generate high-quality HLA- and KIR-disease association data correlated with patient phenotypes that will be submitted to publicly accessible databases.

Description: This program will support retrospective or prospective studies to investigate the relationship between genetic variation in the HLA and KIR regions and immune-mediated diseases. Areas of research may include:

  • The role of donor/recipient HLA and KIR matching in transplantation outcome, graft-versus-host disease, or rate of leukemic relapse following bone marrow transplant
  • Association of HLA and KIR region genes with susceptibility to and progression of immune-mediated diseases and disease phenotype
  • Association of HLA and KIR region variations in food allergy
  • Association of somatic HLA and KIR region variations in cancer susceptibility, phenotype, and prognosis
  • Discovery of novel HLA and KIR region genes associated with immune-mediated diseases or transplantation outcome
  • Mechanistic studies into the basis of HLA and KIR region disease associations

Changes in this renewal:

Expansion of scope to include cancer, pending commitment from the National Cancer Institute.

Immunobiology of Xenotransplantation Cooperative Research Program

Request for Applications—proposed FY 2020 initiative

Contact: Nasrin Nabavi

Objective: The long-term goal of this program is to develop novel and effective strategies for applying xenotransplantation in the clinic. The research focus of this competing renewal initiative is to address the remaining key immunologic and physiologic issues required to achieve safe and efficacious xenotransplantation using preclinical pig to nonhuman primate (NHP) models of pancreatic islet, kidney, heart, lung, or liver xenotransplantation. The goals of this program are to 1) delineate the cellular and molecular mechanisms of xenograft rejection and the induction of tolerance, 2) develop and optimize effective strategies to improve xenograft survival, and 3) characterize and address the physiological compatibility/functions of xenografts post-transplant.

Description: This initiative will support new or competing renewal proposals focused on 1) developing or optimizing genetically-modified models of pig to NHP xenotransplantation of pancreatic islet, kidney, heart, lung, or liver, including optimal combinations of genetic modifications and improved surgical techniques and 2) defining and ultimately resolving the physiological and immunological barriers of successful xenograft application in clinic.

Radiation/Nuclear Countermeasure Product Development Support Services Contract

Request for Proposals—proposed FY 2020 initiative

Contact: Deborah Blyveis

Objective: To provide additional funds to continue and expand nonclinical and clinical efforts for product development of radiation/nuclear medical countermeasure candidate drugs and biodosimetry devices for inclusion in the Strategic National Stockpile for use during a radiation emergency.

Description: The initiative will provide funds to continue and expand product development of radiation countermeasures efforts of the current medical countermeasures against radiological threats: product development support services program. The program will provide a comprehensive and broad range of nonclinical and clinical support services and support continued animal and product development efforts for licensure of both candidate drugs and biodosimetry devices. The types of product development support services will include: screening and efficacy evaluation of candidate drugs; non-good laboratory practice (GLP) and GLP toxicology and safety pharmacology in animal models; current Good Manufacturing Practices manufacturing support; GLP pivotal animal efficacy studies; Phase I clinical safety and pharmacokinetic studies; and regulatory submission support for candidate drugs and biodosimetry devices. This renewal will continue and build upon the previously awarded product support services contracts.

RNCP-Wide Dosimetry Guidance and Monitoring of Sources and Irradiation Protocols

For the published request for proposals, see the January 22, 2019 solicitation, RNCP-Wide Dosimetry Guidance & Monitoring of Sources and Irradiation Protocols (Clinical Trials Not Allowed).

Development of Vaccines for the Treatment of Opioid Use Disorder

For the published broad agency announcement, see the March 20, 2019 solicitation, Development of Vaccines for the Treatment of Opioid Use Disorder.

Characterizing and Improving Humanized Immune System Mouse Models

Broad Agency Announcement—proposed FY 2020 initiative

Contact: Liem Nguyen

Objective:

  • More fully characterize and further develop humanized immune system (HIS) mouse models
  • Conduct direct comparisons of HIS mice derived from fetal versus non-fetal human tissue sources

Description: This is a new initiative and supports research that includes but is not limited to:

  • Optimizing and characterizing HIS mouse models engrafted with fetal or non-fetal tissue sources
  • Direct comparisons of HIS mice generated with human fetal tissue versus non-fetal tissue sources
  • Optimizing and/or developing HIS mouse models that:
    • Recapitulate human innate immunity, T cell function, B cell/antibody responses (subset development and function)
    • Compare engraftment, development, and functional immunity to human pathogens and immune-mediated diseases
    • Demonstrate functional human mucosal immune responses
    • Recapitulate human secondary lymphoid tissue development

Adjuvant Development for Vaccines Against Infectious or Immune-Mediated Diseases

Note: NIAID topic for NIH SBIR contract solicitation.

Request for Proposals

Contact: Charles H. Jackson, Jr.

Adjuvant Discovery for Vaccines Against Infectious or Immune-Mediated Diseases

Note: NIAID topic for NIH SBIR contract solicitation.

Request for Proposals

Contact: Charles H. Jackson, Jr.

Production of Adjuvants

Note: NIAID topic for NIH SBIR contract solicitation.

Request for Proposals

Contact: Charles H. Jackson, Jr.

Reagents for Immunologic Analysis of Non-Mammalian or Underrepresented Mammalian Models

Note: NIAID topic for NIH SBIR contract solicitation.

Request for Proposals

Contact: Charles H. Jackson, Jr.

Content last reviewed on April 1, 2019